CLMT vs TMO · rev $4.19B vs P/E 24, rev $44.56B
Calumet Specialty Products Partners (CLMT) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
Calumet Specialty Products Partners (CLMT) is a specialty chemicals company listed on NASDAQ.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported CLMT revenue for 2024-12-31 was $4.19B. Net income was -$222.0M. Revenue was up 0.2% from 2023-12-31 to 2024-12-31. CLMT currently screens at market cap $2.89B.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
CLMT currently screens at market cap $2.89B. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the CLMT and TMO stock pages for the full models.
Not investment advice.